◎ Sugi Atlas

Atlas / Gene / ABTB3

ABTB3

gene
On this page

Also known as FLJ33957ABTB2B

Summary

ABTB3 (ankyrin repeat and BTB domain containing 3, HGNC:23844) is a protein-coding gene on chromosome 12q23.3, encoding Ankyrin repeat- and BTB/POZ domain-containing protein 3 (A6QL63). Cortical and hippocampal inhibitory interneuron-specific protein localized at glutamatergic (excitatory) synapses, where it supports cell type-specific synaptic function.

Predicted to enable PDZ domain binding activity and protein heterodimerization activity. Predicted to act upstream of or within exploration behavior; glutamatergic synaptic transmission; and protein stabilization. Predicted to be located in glutamatergic synapse and membrane.

Source: NCBI Gene 121551 — RefSeq curated summary.

At a glance

  • GWAS associations: 13
  • Clinical variants (ClinVar): 179 total — 1 likely-pathogenic
  • MANE Select transcript: NM_001018072

Identifiers

Gene identifiers

FieldValue
HGNC IDHGNC:23844
Approved symbolABTB3
Nameankyrin repeat and BTB domain containing 3
Location12q23.3
Locus typegene with protein product
StatusApproved
AliasesFLJ33957, ABTB2B
Ensembl geneENSG00000151136
Ensembl biotypeprotein_coding
OMIM621028
Entrez121551

Gene structure

Transcript identifiers

Ensembl transcripts: 7 — 7 protein_coding

ENST00000280758, ENST00000357167, ENST00000415943, ENST00000420571, ENST00000490090, ENST00000494235, ENST00000550706

RefSeq mRNA: 4 — MANE Select: NM_001018072 NM_001017523, NM_001018072, NM_001347943, NM_001347944

CCDS: CCDS31893, CCDS41827, CCDS86332

Canonical transcript exons

ENST00000280758 — 17 exons

ExonStartEnd
ENSE00000997870107651674107651787
ENSE00001385400107657509107659642
ENSE00001790674107318434107320075
ENSE00002325424107615061107615162
ENSE00002333038107617301107617436
ENSE00002340564107520487107520636
ENSE00002345127107642090107642171
ENSE00002345421107581152107581304
ENSE00002363193107649206107649274
ENSE00002386351107612780107612869
ENSE00002404677107618158107618378
ENSE00002406539107610190107610355
ENSE00002411070107543935107544139
ENSE00002419232107619986107620164
ENSE00002424050107617089107617182
ENSE00003491686107635285107635390
ENSE00003609733107640311107640413

Expression profiles

Bgee: expression breadth ubiquitous, 205 present calls, max score 91.52.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.5724 / max 212.9012, expressed in 1046 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter IDTPM avgSamples expressed
1278495.43501027
1278570.118057
1278560.019514

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

TissueAnatomy IDExpression scoreQuality
lower esophagus mucosaUBERON:003583491.52gold quality
esophagus squamous epitheliumUBERON:000692091.05gold quality
upper arm skinUBERON:000426390.88gold quality
esophagus mucosaUBERON:000246988.77gold quality
gingivaUBERON:000182888.48gold quality
gingival epitheliumUBERON:000194988.37gold quality
oral cavityUBERON:000016783.35gold quality
right lobe of thyroid glandUBERON:000111981.45gold quality
pancreatic ductal cellCL:000207981.24silver quality
upper leg skinUBERON:000426281.24gold quality
left lobe of thyroid glandUBERON:000112081.16gold quality
thyroid glandUBERON:000204680.94gold quality
skin of abdomenUBERON:000141680.08gold quality
lateral nuclear group of thalamusUBERON:000273679.61gold quality
skin of legUBERON:000151179.21gold quality
zone of skinUBERON:000001479.19gold quality
hypothalamusUBERON:000189878.84gold quality
skin of hipUBERON:000155478.74gold quality
secondary oocyteCL:000065578.22gold quality
prefrontal cortexUBERON:000045178.08gold quality
primary visual cortexUBERON:000243677.98gold quality
kidney epitheliumUBERON:000481977.93gold quality
anterior cingulate cortexUBERON:000983577.85gold quality
substantia nigra pars compactaUBERON:000196577.80gold quality
islet of LangerhansUBERON:000000677.78gold quality
middle temporal gyrusUBERON:000277177.70gold quality
substantia nigraUBERON:000203876.10gold quality
ponsUBERON:000098876.08gold quality
midbrainUBERON:000189175.74gold quality
vaginaUBERON:000099675.68gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 5.

ExperimentMarker?Max mean expression
E-HCAD-35yes64.46
E-CURD-119yes41.46
E-HCAD-25yes40.12
E-MTAB-6075yes20.15
E-ANND-3yes5.70

Regulation

Is transcription factor: no

Cross-species orthologs

8 orthologs

OrganismSymbolGene ID
danio_reriobtbd11bENSDARG00000063040
danio_reriobtbd11aENSDARG00000063255
mus_musculusAbtb3ENSMUSG00000020042
rattus_norvegicusAbtb3ENSRNOG00000005758
drosophila_melanogasterBTBD9FBGN0030228
drosophila_melanogasterCG17068FBGN0031098
drosophila_melanogasterluteFBGN0262871
caenorhabditis_elegansWBGENE00015463

Paralogs (11): BTBD1 (ENSG00000064726), ABTB1 (ENSG00000114626), SPOP (ENSG00000121067), KBTBD4 (ENSG00000123444), BTBD3 (ENSG00000132640), BTBD2 (ENSG00000133243), SPOPL (ENSG00000144228), ABTB2 (ENSG00000166016), KLHL11 (ENSG00000178502), BTBD9 (ENSG00000183826), BTBD6 (ENSG00000184887)

Protein

Protein identifiers

Ankyrin repeat- and BTB/POZ domain-containing protein 3 — A6QL63 (reviewed: A6QL63)

Alternative names: BTB/POZ domain-containing protein 11

All UniProt accessions (3): A6QL63, C9JV03, H0YHR1

UniProt curated annotations — full annotation on UniProt →

Function. Cortical and hippocampal inhibitory interneuron-specific protein localized at glutamatergic (excitatory) synapses, where it supports cell type-specific synaptic function.

Subunit / interactions. Interacts with core postsynaptic proteins, including DLG4; interaction with DLG4 stabilizes DLG4 at glutamatergic synapses.

Subcellular location. Membrane.

Induction. By all-trans retinoic acid (ATRA).

Isoforms (5)

UniProt IDNamesCanonical?
A6QL63-11yes
A6QL63-22
A6QL63-33
A6QL63-44
A6QL63-55

RefSeq proteins (4): NP_001017523, NP_001018082, NP_001334872, NP_001334873 (=MANE)

Domains & families (InterPro)

IDNameType
IPR000210BTB/POZ_domDomain
IPR002110Ankyrin_rptRepeat
IPR009072Histone-foldHomologous_superfamily
IPR011333SKP1/BTB/POZ_sfHomologous_superfamily
IPR036770Ankyrin_rpt-contain_sfHomologous_superfamily
IPR047824BTBD11_BACKDomain
IPR052089Ankyrin-BTB/POZ_domainFamily
IPR059008ABTB2/3_histoneDomain

Pfam: PF00023, PF00651, PF12796, PF26281

UniProt features (22 total): splice variant 5, repeat 5, sequence conflict 4, sequence variant 3, chain 1, transmembrane region 1, domain 1, region of interest 1, compositionally biased region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

ModelpLDDTFraction very-high
AF-A6QL63-F173.180.34

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 198 (showing top): MYOGENIN_Q6, GOBP_BEHAVIOR, PEREZ_TP63_TARGETS, CAGCTG_AP4_Q5, RODWELL_AGING_KIDNEY_NO_BLOOD_DN, GOBP_CELL_CELL_SIGNALING, MYOD_01, GOBP_PROTEIN_STABILIZATION, BACH2_01, TGANTCA_AP1_C, GOBP_REGULATION_OF_PROTEIN_STABILITY, GOBP_SYNAPTIC_SIGNALING, PEREZ_TP53_AND_TP63_TARGETS, CREB_Q3, GOBP_EXPLORATION_BEHAVIOR

GO Biological Process (3): synaptic transmission, glutamatergic (GO:0035249), exploration behavior (GO:0035640), protein stabilization (GO:0050821)

GO Molecular Function (3): PDZ domain binding (GO:0030165), protein heterodimerization activity (GO:0046982), protein binding (GO:0005515)

GO Cellular Component (2): membrane (GO:0016020), glutamatergic synapse (GO:0098978)

GO top-level categories

Rollup of top GO terms by namespace:

CategoryTerms
chemical synaptic transmission1
behavior1
regulation of protein stability1
protein domain specific binding1
protein dimerization activity1
binding1
cellular anatomical structure1
synapse1

Protein interactions and networks

STRING

560 interactions, top by confidence (×1000):

Protein AProtein BPartner UniProtScore
ABTB3CCDC166P0CW27447
ABTB3ARHGEF15O94989441
ABTB3SLC35E3Q7Z769386
ABTB3RNF217Q8TC41384
ABTB3KLHL34Q8N239364
ABTB3UPF1Q92900353
ABTB3SLC25A48Q6ZT89349
ABTB3PPP1R3EQ9H7J1329
ABTB3RIC8BQ9NVN3327
ABTB3DCXRQ7Z4W1320
ABTB3PPFIBP1Q86W92318
ABTB3DPY19L1Q2PZI1312
ABTB3ANKRD24Q8TF21311
ABTB3GRAMD1CQ8IYS0310
ABTB3CRACDLQ6NV74309
ABTB3BTBD6Q96KE9309

IntAct

7 interactions, top by confidence:

ABTypeScore
MAP1LC3BABTB3psi-mi:“MI:0407”(direct interaction)0.440
MAP1LC3AABTB3psi-mi:“MI:0407”(direct interaction)0.440
ABTB2IFT56psi-mi:“MI:0914”(association)0.350
KLHL22TRAV18psi-mi:“MI:0914”(association)0.350
CEP83ABTB3psi-mi:“MI:2364”(proximity)0.270
TIAM1ABTB3psi-mi:“MI:0915”(physical association)0.000

BioGRID (16): BTBD11 (Proximity Label-MS), BTBD11 (Affinity Capture-Western), BTBD11 (Proximity Label-MS), BTBD11 (Affinity Capture-MS), BTBD11 (Affinity Capture-MS), BTBD11 (Protein-peptide), BTBD11 (Protein-peptide), BTBD11 (Two-hybrid), BTBD11 (Affinity Capture-MS), BTBD11 (Affinity Capture-RNA), BTBD11 (Proximity Label-MS), BTBD11 (Proximity Label-MS), BTBD11 (Proximity Label-MS), BTBD11 (Proximity Label-MS), BTBD11 (Proximity Label-MS)

ESM2 similar proteins: A0M8S0, A0M8T1, A0M8U1, A3KN28, A4D7R9, A6QL63, A9JRA0, B5DEN9, P13666, Q00PJ0, Q07DV5, Q07DW9, Q07DX8, Q07DY8, Q07E08, Q07E45, Q09YH4, Q09YI5, Q09YJ7, Q09YK8, Q09YN2, Q108U3, Q1RLU8, Q2IBA8, Q2IBD0, Q2IBE0, Q2IBE8, Q2PG42, Q2QL86, Q2QLA6, Q2QLB7, Q2QLD7, Q2QLE8, Q2QLG2, Q3T178, Q5R8N4, Q68FW3, Q6ZUT9, Q7TQ48, Q7Z3J2

Diamond homologs: A5DJJ2, A6QL63, B1WBU4, B7U179, B9DHT4, O08764, P0C7A6, Q0VCJ6, Q1LVW0, Q5XI58, Q5ZJU2, Q6GQW0, Q6YCH2, Q7KRI2, Q7TQI7, Q811F1, Q8CDE2, Q8N961, Q96BR9, Q9CWH1, A0JMG1, A1L4W5, A2AAX3, A9JRD8, D3ZA50, D4A2K4, G3LSH3, G8GTN7, O43791, O94955, P0DMR5, P0DMR6, P34568, Q08CY1, Q08DS0, Q0IHH9, Q0V9W6, Q0VCW1, Q2HW56, Q2LE78

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

179 variants total. Per-class counts are floors (≥ shown; pagination cap):

ClassificationCount (floor)
Pathogenic0
Likely pathogenic1
Uncertain significance154
Likely benign7
Benign0

Top pathogenic / likely-pathogenic (1)

Variant IDHGVSClassification
1527730GRCh37/hg19 12q23.2-24.11(chr12:103044333-111639805)Likely pathogenic

SpliceAI

3667 predictions. Top by Δscore:

VariantEffectΔscore
12:107320073:GCG:Gdonor_gain1.0000
12:107320074:CGG:Cdonor_loss1.0000
12:107320075:GGT:Gdonor_loss1.0000
12:107320076:G:GCdonor_loss1.0000
12:107320077:T:Adonor_loss1.0000
12:107520467:T:TAacceptor_gain1.0000
12:107520478:T:Aacceptor_gain1.0000
12:107520482:TGCA:Tacceptor_loss1.0000
12:107520483:GCAG:Gacceptor_loss1.0000
12:107520484:CA:Cacceptor_loss1.0000
12:107520485:A:AGacceptor_gain1.0000
12:107520485:A:ATacceptor_loss1.0000
12:107520485:AG:Aacceptor_gain1.0000
12:107520485:AGG:Aacceptor_gain1.0000
12:107520485:AGGG:Aacceptor_gain1.0000
12:107520486:G:GCacceptor_gain1.0000
12:107520486:GG:Gacceptor_gain1.0000
12:107520486:GGG:Gacceptor_gain1.0000
12:107520486:GGGG:Gacceptor_gain1.0000
12:107520486:GGGGT:Gacceptor_gain1.0000
12:107520632:ATTGA:Adonor_gain1.0000
12:107520633:TTGA:Tdonor_gain1.0000
12:107520634:TGA:Tdonor_gain1.0000
12:107520635:GA:Gdonor_gain1.0000
12:107520635:GAG:Gdonor_gain1.0000
12:107520636:AG:Adonor_loss1.0000
12:107520637:G:Cdonor_loss1.0000
12:107520637:G:GGdonor_gain1.0000
12:107520638:T:Adonor_loss1.0000
12:107543929:CCACA:Cacceptor_loss1.0000

AlphaMissense

7209 scored. Top likely-pathogenic:

VariantProtein changeam_pathogenicity
12:107520634:T:CL428S1.000
12:107520634:T:GL428W1.000
12:107543941:T:CL431P1.000
12:107544033:T:AW462R1.000
12:107544033:T:CW462R1.000
12:107544058:T:CL470P1.000
12:107581183:T:AW508R1.000
12:107581183:T:CW508R1.000
12:107581185:G:CW508C1.000
12:107581185:G:TW508C1.000
12:107581247:T:AV529D1.000
12:107581259:C:AA533D1.000
12:107581268:T:CL536P1.000
12:107581271:T:CL537P1.000
12:107617093:T:CL669P1.000
12:107617325:T:CL707P1.000
12:107617430:G:AG742E1.000
12:107617430:G:TG742V1.000
12:107618175:T:CL750P1.000
12:107618330:A:CS802R1.000
12:107618332:C:AS802R1.000
12:107618332:C:GS802R1.000
12:107619994:T:AW821R1.000
12:107619994:T:CW821R1.000
12:107620009:T:AW826R1.000
12:107620009:T:CW826R1.000
12:107620070:T:CL846S1.000
12:107635307:T:CL885P1.000
12:107635333:G:TG894W1.000
12:107635334:G:AG894E1.000

dbSNP variants (sampled 300 via entrez): RS1000013886 (12:107655602 T>C), RS1000020949 (12:107372099 G>A), RS1000024997 (12:107583840 TC>T), RS1000046037 (12:107563627 A>G), RS1000054274 (12:107358074 C>G,T), RS1000071823 (12:107333747 G>A), RS1000072354 (12:107364175 C>T), RS1000077375 (12:107584223 A>G), RS1000082401 (12:107500626 C>G,T), RS1000095005 (12:107521464 G>A), RS1000112351 (12:107336903 AC>A), RS1000121097 (12:107569762 A>T), RS1000144043 (12:107401298 G>A), RS1000145743 (12:107620226 C>A), RS1000149946 (12:107482094 G>A,C,T)

Disease associations

OMIM: gene MIM:621028 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

13 associations (top):

StudyTraitp-value
GCST000477_40Cognitive performance8.000000e-06
GCST002408_11Response to methotrexate in juvenile idiopathic arthritis4.000000e-06
GCST002481_2Acne (severe)5.000000e-06
GCST003098_22Diabetic kidney disease2.000000e-06
GCST003830_21Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)2.000000e-07
GCST003830_7Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1)1.000000e-07
GCST003859_1Oropharynx cancer2.000000e-06
GCST005194_186Coronary artery disease9.000000e-06
GCST008226_1Renal cell carcinoma2.000000e-08
GCST008862_3Triacylglycerol 56:6 levels4.000000e-07
GCST009179_11Pars triangularis volume2.000000e-06
GCST010923_5Beta blocker survival benefit in heart failure with reduced ejection fraction (time to all cause mortality x beta blocker interaction)3.000000e-06
GCST012048_15Triglyceride levels1.000000e-07

EFO canonical traits (5, from GWAS)

EFO IDTrait name
EFO:0003926neuropsychological test
EFO:0005921FEV change measurement
EFO:0004530triglyceride measurement
EFO:0004352mortality
EFO:0007766response to beta blocker

MeSH disease descriptors (1)

DescriptorNameTree numbers
D011471Prostatic NeoplasmsC04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

42 total (human), top 30 by PubMed support.

ChemicalActions (top 5)PubMed papers
Valproic Acidaffects cotreatment, increases expression, affects expression6
Benzo(a)pyreneaffects methylation, decreases expression5
trichostatin Aaffects cotreatment, decreases expression3
Tobacco Smoke Pollutiondecreases expression, increases expression3
Vorinostatdecreases expression, affects cotreatment2
Cisplatindecreases expression, increases expression2
Tetrachlorodibenzodioxindecreases expression2
Tretinoinincreases expression2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxidedecreases expression2
Aflatoxin B1affects expression, decreases methylation2
aristolochic acid Idecreases expression1
GSK-J4increases expression1
tris(2-butoxyethyl) phosphateaffects expression1
sodium arseniteaffects methylation1
butyraldehydedecreases expression1
benzo(e)pyreneincreases methylation1
beta-methylcholineaffects expression1
K 7174increases expression1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamideaffects cotreatment, increases expression, decreases expression1
abrinedecreases expression1
dorsomorphinaffects cotreatment, increases expression, decreases expression1
Temozolomidedecreases expression1
Sunitinibincreases expression1
Zoledronic Aciddecreases expression1
Leflunomideincreases expression1
Air Pollutantsdecreases expression1
Arsenicaffects methylation1
Benzeneincreases expression1
Carbamazepineaffects expression1
Diethylhexyl Phthalatedecreases expression1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

TrialPhaseStatusTitle
NCT00029224PHASE4COMPLETEDTreatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997PHASE4COMPLETEDOpen-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609PHASE4COMPLETEDThe Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623PHASE4SUSPENDEDThe Plenaxis® Experience Study
NCT00106392PHASE4COMPLETEDA Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029PHASE4UNKNOWNMR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485PHASE4COMPLETEDAngelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219PHASE4COMPLETEDZoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271PHASE4COMPLETEDEffect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146PHASE4COMPLETEDStudy to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554PHASE4COMPLETEDOpen-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098PHASE4COMPLETEDDocetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696PHASE4COMPLETEDCasodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139PHASE4COMPLETEDEffect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765PHASE4COMPLETEDEffects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690PHASE4COMPLETEDEvaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708PHASE4COMPLETEDLocal Anesthesia for Prostate Biopsy
NCT00526331PHASE4COMPLETEDEvaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213PHASE4COMPLETEDCompare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330PHASE4TERMINATEDDissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966PHASE4COMPLETEDRadical Prostatectomy and Perioperative Fluid Therapy
NCT00805701PHASE4COMPLETEDStudy Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027PHASE4COMPLETEDEffect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269PHASE4UNKNOWNCan Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277PHASE4COMPLETEDStudy of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800PHASE4COMPLETEDDoes Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199PHASE4COMPLETEDGlobal Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226PHASE4COMPLETEDEvaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563PHASE4COMPLETEDRandomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905PHASE4COMPLETEDStudy to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672PHASE4COMPLETED3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143PHASE4TERMINATEDProspective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742PHASE4UNKNOWNComparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563PHASE4COMPLETEDHydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874PHASE4COMPLETEDEfficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472PHASE4TERMINATEDFirmagon (Degarelix) Intermittent Therapy
NCT01547416PHASE4COMPLETEDThe Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544PHASE4COMPLETEDThe Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749PHASE4UNKNOWNEvaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635PHASE4COMPLETEDStudy of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 74

This page pulls from 74 datasets indexed by BioBTree:

alphafoldalphamissenseantibodybgeebgee_evidencebindingdbbiogrid_interactionbrendabrenda_kineticsccdscellosauruschembl_activitychembl_targetciviccivic_evidenceclingen_dosageclingen_gene_validityclinical_trialsclinvarcollectrictd_gene_interactiondbsnpdepmapdiamond_similarityefoensemblentrezesm2_similarityexonfantom5_genefantom5_promotergenccgenerifgogoparentgtopdbgwasgwas_studyhgnchpointactinterprointogenjasparmeshmimmirdbmondomsigdborphanetorthologparalogpdbpfampharmgkb_clinicalpharmgkb_genepharmgkb_guidelinepharmgkb_variantpubchempubchem_activitypubchem_assaypubmedreactomerefseqrhearnacentralscxa_expressionscxa_gene_experimentsignorspliceaistring_interactiontranscriptufeatureuniprot